WO1998056338A1 - Produit cosmetique eclaircissant la peau - Google Patents
Produit cosmetique eclaircissant la peau Download PDFInfo
- Publication number
- WO1998056338A1 WO1998056338A1 PCT/JP1998/002548 JP9802548W WO9856338A1 WO 1998056338 A1 WO1998056338 A1 WO 1998056338A1 JP 9802548 W JP9802548 W JP 9802548W WO 9856338 A1 WO9856338 A1 WO 9856338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- unsaturated fatty
- salts
- fatty acids
- phospholipid
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 47
- 206010040829 Skin discolouration Diseases 0.000 title abstract 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 49
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 29
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 22
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 230000002087 whitening effect Effects 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 22
- 239000002502 liposome Substances 0.000 claims description 14
- 108010035532 Collagen Proteins 0.000 claims description 13
- 102000008186 Collagen Human genes 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 229920001436 collagen Polymers 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000000413 hydrolysate Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 5
- 102000016942 Elastin Human genes 0.000 claims description 5
- 108010014258 Elastin Proteins 0.000 claims description 5
- 239000007857 degradation product Substances 0.000 claims description 5
- 229920002549 elastin Polymers 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 abstract description 22
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000008213 purified water Substances 0.000 description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 28
- 208000012641 Pigmentation disease Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 230000019612 pigmentation Effects 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- -1 linoleic acid, phospholipids Chemical class 0.000 description 18
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 17
- 235000006708 antioxidants Nutrition 0.000 description 17
- 235000020778 linoleic acid Nutrition 0.000 description 17
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 229930003427 Vitamin E Natural products 0.000 description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 14
- 239000011709 vitamin E Substances 0.000 description 14
- 235000019165 vitamin E Nutrition 0.000 description 14
- 229940046009 vitamin E Drugs 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 239000000787 lecithin Substances 0.000 description 11
- 229940067606 lecithin Drugs 0.000 description 11
- 235000010445 lecithin Nutrition 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 210000003705 ribosome Anatomy 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000010979 pH adjustment Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 150000005846 sugar alcohols Polymers 0.000 description 8
- 229940058015 1,3-butylene glycol Drugs 0.000 description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940031016 ethyl linoleate Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 108010045569 atelocollagen Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 239000004318 erythorbic acid Substances 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940040452 linolenate Drugs 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UAERWSVCVIITFA-ISKARVOYSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(9z,12z)-octadeca-9,12-dienoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O UAERWSVCVIITFA-ISKARVOYSA-N 0.000 description 1
- FBZQBGYPONNWCG-UHFFFAOYSA-N (4,5-dihydroxy-2,3-dimethoxyphenyl)-phenylmethanone Chemical compound COC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1OC FBZQBGYPONNWCG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- VQSASUJRHSDKFK-IFNWOZJISA-N 2-hydroxyethylazanium;(9z,12z,15z)-octadeca-9,12,15-trienoate Chemical compound [NH3+]CCO.CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O VQSASUJRHSDKFK-IFNWOZJISA-N 0.000 description 1
- KNUPSOXBESCJLY-UHFFFAOYSA-N 2-methoxy-1-phenylhexan-1-one Chemical compound CCCCC(OC)C(=O)C1=CC=CC=C1 KNUPSOXBESCJLY-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 108010030727 lens intermediate filament proteins Proteins 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LUMVCLJFHCTMCV-UHFFFAOYSA-M potassium;hydroxide;hydrate Chemical compound O.[OH-].[K+] LUMVCLJFHCTMCV-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical compound OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- WYPBVHPKMJYUEO-NBTZWHCOSA-M sodium;(9z,12z)-octadeca-9,12-dienoate Chemical compound [Na+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O WYPBVHPKMJYUEO-NBTZWHCOSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Definitions
- the present invention relates to a whitening cosmetic which eliminates, darkens or prevents skin pigmentation such as darkening or spots and freckles due to ultraviolet rays.
- spot pigmentation disorder such as a liver spot or a senile pigment spot. It is known that these pigmentation disorders are exacerbated by ultraviolet rays, and ultraviolet protective agents and the like have been used to prevent this. Also, whitening cosmetics using vitamin c, placenta extract, kojic acid, arbutin, unsaturated fatty acids, etc. as active ingredients have been known to reduce the already developed pigmentation disorders. Among them, unsaturated fatty acids represented by linoleic acid (linoleic acid or linoleic acid) are known to have an excellent effect of lightening pigmentation formed on skin (Japanese Journal of Cosmetic Engineers 27, pp. 415-423, 1993).
- the present invention provides a whitening cosmetic composition containing an unsaturated fatty acid or a derivative thereof as an active ingredient, having a lower concentration, having a high effect of lightening pigmentation formed on the skin, and having excellent safety.
- the purpose is to: Disclosure of the invention
- the present inventors have conducted intensive studies to achieve the above-mentioned object.
- unsaturated fatty acids such as linoleic acid, phospholipids, antioxidants, proteins or their hydrolyzates.
- whitening cosmetics containing polysaccharides or salts thereof are effective in lightening pigmentation and have high safety even when low-concentration unsaturated fatty acids are added. I came to.
- the present invention provides a whitening cosmetic composition
- a whitening cosmetic composition comprising
- the whitening cosmetic of the present invention is preferably one in which a ribosome complex containing the above (A) to (E) is combined.
- the present invention also provides a whitening cosmetic containing a complex (ribosome) containing the above component.
- Fig. 1 is a graph showing the relationship between the number of days elapsed and the lightening effect when a whitening cosmetic is applied.
- FIG. 2 is a graph showing the relationship between elapsed time and skin permeability of unsaturated fatty acids when a whitening cosmetic is applied.
- the unsaturated fatty acid and its derivative used in the cosmetic of the present invention have a fatty acid moiety of 18 to 22 carbon atoms and 2 to 6 double bonds in the molecular structure.
- fatty acids include linoleic acid (linoleic acid or 1 inolic acid), hyalinolenic acid, alinolenic acid, dihomoalinolenic acid, arachidonic acid, eicosapen.
- Free unsaturated fatty acids such as taenoic acid and docosahexanoic acid; unsaturated fatty acid metal salts such as sodium linoleate and potassium linolenate; unsaturated such as arginine linoleate and lysine ⁇ -linolenate Fatty acid amino acid salts; unsaturated fatty acid amine salts such as linoleic acid triethanolamine salt and ⁇ -linolenic acid monoethanolamine salt; and ethyl ethyl linoleate, ethyl ethyl monolinoleate, monoglyceride linoleic acid, ⁇ -linolenic acid Monoesters of unsaturated fatty acids such as acid monoglyceride, linoleic acid diglyceride, ⁇ -linolenic acid diglyceride, etc.
- Esters der connexion, triglyceride of unsaturated fatty acids contained like ordinary vegetable oils and fats are excluded.
- preferred are linoleic acid, monolinolenic acid, ethyl linoleate, ethyl ethyl ⁇ -linolenate, monoglyceride linoleate, and monoglyceride ⁇ -linolenate, with linoleic acid being particularly preferred.
- These unsaturated fatty acids and derivatives thereof may be used alone or in combination of two or more.
- the content of these unsaturated fatty acids and derivatives thereof in the cosmetic is preferably 0.01 to 0.7% by weight, more preferably 0.03 to 5% by weight, and most preferably 0.05 to 5% by weight. ⁇ 3% by weight. If the amount is less than the above range, the effect of lightening pigmentation may not be sufficient. There is no tendency.
- the phospholipids include, for example, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylglycerol, sphingomyelin, soybean lecithin, corn lecithin, cottonseed oil lecithin, egg yolk lecithin
- examples include natural lecithin such as lecithin, hydrogenated lecithin, and phospholipid derivatives obtained by introducing polyethylene glycol and aminoglycans into these phospholipids.
- These phospholipids can be used alone or in combination of two or more. Of these, soybean lecithin, egg yolk lentin, hydrogenated soybean lecithin, and hydrogenated egg yolk lecithin are preferred.
- the content of the phospholipid in the cosmetic is preferably 0.05 to 10% by weight, and more preferably 0.20 to 2% by weight. If the compounding amount is less than the above range, the effect of lightening pigmentation may not be recognized, and if the amount exceeds this range, the effect does not tend to increase.
- antioxidants include dibutyl hydroquine toluene, butylhydroxyxanisole, vitamin E and its derivatives, vitamin C and its derivatives, erythorbic acid and its salts, genoshocoex, hamamelis extract, and chilla Extracts such as plant extracts and gallic acid esters are exemplified.
- vitamin E, dibutylhydroxytoluene, butylhydroxyanisole, and gallic acid ester are preferred, and vitamin E is particularly preferred.
- These antioxidants can be used alone or in combination of two or more.
- the compounding amount of these antioxidants is preferably 0.05 to 0.5% by weight, more preferably 0.01 to 0.2% by weight. If the amount is less than this, the effect of lightening pigmentation may not be sustained, whereas if it is more than this, the stability of the preparation may be reduced.
- the (D) protein and its hydrolyzate used in the present invention include collagen, elastin, keratin, casein, their hydrolysates, hydrolysate salts, hydrolysate esters, and enzymatically treated ones. And the like.
- collagen, elastin and their hydrolysates, hydrolysate salts, and hydrolysate esters are preferred.
- Hydrolyzed collagen, atelocollagen, and hydrolyzed caseinna are preferred. Examples include thorium, hydrolyzed collagen ethyl, and water-soluble collagen. These proteins and hydrolysates thereof may be used alone or in appropriate combination of two or more kinds.
- the amount of these components is preferably 0.01 to 0.5% by weight, more preferably 0.01 to 1% by weight. If the compounding amount is less than the above range, the effect of lightening of color deposition may not be recognized, whereas if the compounding amount exceeds the above range, the effect tends to be unchanged.
- Examples of the (E) mucopolysaccharide include chondroitin sulfate, hyaluronic acid, dermatan sulfate, heparan sulfate, mucotine sulfate, heparin and derivatives thereof, and sodium salts and potassium salts thereof. Chondroitin sulfate, hyaluronic acid and their sodium salts are preferred.
- the mucopolysaccharide may be derived from a natural source or may be produced by a biochemical method or the like. These mucopolysaccharides may be used alone or in combination of two or more.
- the amount of the mucopolysaccharide is preferably 0.005 to 0.5% by weight, more preferably 0.001 to 1% by weight. If the amount is less than this range, the effect of lightening pigmentation is small, while if it exceeds this range, the feeling of use may be impaired.
- the components (A) to (E) are mixed and processed according to a conventional method according to the form of the cosmetic, and a milky lotion, a cream, a lotion, a beauty lotion, a cleaning solution, Ordinary preparations such as packs and face wash can be used.
- a ribosome complex containing the above-mentioned components (A) to (E) can be prepared in advance, and then used in a desired formulation.
- a liposome complex When such a liposome complex is used, a high whitening effect is obtained at an extremely low concentration, the stability of the active ingredient is improved, and the deterioration of the cosmetic is reduced.
- the first method for producing a ribosome complex comprises:
- the second method for producing a ribosome complex comprises: (A) an unsaturated fatty acid and a derivative thereof in a mixed solution containing (D) a protein and a hydrolyzate thereof, and (E) a mucopolysaccharide.
- a preferred form of the whitening cosmetic of the present invention is a cosmetic in which a ribosome complex containing the above-mentioned components is prepared in advance and blended into a desired preparation.
- a cosmetic medium those obtained by mixing and dispersing a ribosome complex in a cosmetic medium are preferable, and a water-soluble cosmetic medium is particularly preferable, and examples thereof include a lotion, a gel cosmetic, a serum, and an oil-in-water emulsifier.
- a ribosome containing (A) an unsaturated fatty acid and its derivative, (B) a phospholipid, and (C) an antioxidant is obtained as in the following 1-4.
- a method for preparing a liposome by mixing and dissolving phospholipids, unsaturated fatty acids or their salts or esters, and an antioxidant in ethanol, adding this ethanol solution to an aqueous solution of potassium chloride, and then removing the ethanol. And the like.
- the liposome dispersion obtained in this manner is adjusted to the particle size by passing through a filter as necessary, and carboxyvinyl polymer, carboxymethylcellulose, hydroxyethylcellulose is used to improve stability.
- Xanthan gum poly (oxyethylene) -poly (oxypropylene) block polymer
- other high-molecular substances such as citric acid, citrate, phosphoric acid, phosphate, triethanolamine, potassium hydroxide, sodium hydroxide, PH adjusters such as lactic acid and lactate, polyhydric alcohols such as glycerin, propylene glycol and butylene glycol, polysaccharides such as alginates and alginates, saccharides such as trehalose, glucose, sorbitol and sucrose, and cholesterol Good .
- the molar ratio of unsaturated fatty acids or salts or esters thereof to ribosomes and phospholipids is preferably in the range of 1: 5 to 2: 1, and the whitening effect is particularly enhanced at a molar ratio of 1: 2 to 3: 2.
- the liposome dispersion prepared by any one of the above methods is dispersed in an aqueous solution containing a protein or its decomposed product and mucopolysaccharide, and phospholipids, unsaturated fatty acids or salts or esters thereof, and antioxidants are prepared.
- a liposome complex containing the drug, protein and mucopolysaccharide is obtained.
- a ribosome containing components (A), (B), and (C) is formed in a mixed solution containing components (D) and (E) as shown in the following 1-3. This is done by doing.
- the liposome composite dispersion obtained in the above-mentioned preparation method B (1) to (3) may be passed through a filter as necessary to adjust the particle size or to increase the stability.
- High molecular substances such as carboxyvinyl polymer, carboxymethylcellulose, hydroxyethyl cellulose, xanthan gum, poly (oxyethylene) -poly (oxypropylene) block polymer, etc., and citric acid, citrate, and phosphoric acid PH adjusters such as phosphates, phosphate salts, sodium hydroxide, sodium hydroxide, lactic acid, and lactate; polyhydric alcohols such as glycerin, propylene glycol, butylene glycol, alginates, and alginates Polysaccharides, such as trehalose, glucose, sorbitol, sucrose, cholesterol, It may be added.
- the molar ratio of unsaturated fatty acids or their salts or esters forming ribosomes to phospholipids is preferably in the range of 1: 5 to 2: 1, and the whitening effect is particularly enhanced at a molar ratio of 1: 2 to 3: 2. .
- the whitening cosmetic thus obtained has a high effect of lightening the pigmentation formed on the skin even with a significantly lower concentration of unsaturated fatty acids than before, and is excellent in safety.
- the whitening cosmetic of the present invention may contain, if necessary, an anti-inflammatory agent, an ultraviolet absorber or an ultraviolet scattering agent, a whitening agent other than the essential component (A) of the present invention, an oil agent, a surfactant, and a moisturizer.
- an anti-inflammatory agent an ultraviolet absorber or an ultraviolet scattering agent
- a whitening agent other than the essential component (A) of the present invention an oil agent, a surfactant, and a moisturizer.
- Agents, animal and plant extracts, pH adjusters, coloring agents, fragrances, preservatives, chelating agents, and the like can be appropriately compounded within a range that does not impair the effects of the present invention.
- anti-inflammatory agents include, for example, allantoin, epsilon aminocaproic acid, glycyrrhetinic acid, glycyrrhizic acid, salts and derivatives thereof, Photosensitizer 301, Photosensitizer 401, diphenylhydramine hydrochloride, water-soluble Azulene (1,4-dimethyl — 7-Isopropylazulene-1-sulfonate) Adenosine-phosphoric acid, purple root extract, Toki extract, mugwort extract, permoko extract, etc., and one or more of these can be blended.
- the compounding amount of these anti-inflammatory agents is preferably from 0.01 to 5% by weight.
- ultraviolet absorbers examples include perlocanilic acid, ethyl perlocnate, oxybenzon, oxybenzonesulfonic acid, tetrahydroxybenzophenone, dihydroxydimethoxybenzobenzophenone sodium sulfonate, dihydroxydimethoxybenzophenone, and dihydroxybenzo.
- the compounding amount of these ultraviolet absorbing or scattering agents can be 0.05 to 25% by weight.
- a whitening agent other than the essential component (A) of the present invention may be used in combination, for example, ascorbic acid and its salts or esters, placental extract, kojic acid and its salts or esters, glucosamine and its salts or esters, and azeline Acid and its salt or ester, retinol and its salt or ester, pyridoxine and its salt or ester, tranexamic acid and its salt or ester, arbutin, photosensitizer, io, 4-hydroxy gay cinnamate, carrot extract, One or more kinds such as licorice extract can be blended, and the blending amount can be 0.1 to 10.0% by weight.
- Lecithin or hydrogenated lecithin, unsaturated fatty acids, and vitamin E were mixed homogeneously with 1,3-butylene glycol.
- this mixed solution was added to a solution of collagen and sodium chondroitin sulfate in purified water, mixed, stirred, and treated with a French press to form a liposome complex.
- This liposomal complex was added to purified water in which 1,3-butylene glycol, carboxyvinyl polymer, potassium hydroxide, and methyl para-oxybenzoate were dissolved and mixed with stirring to prepare a serum.
- a solvent such as methylene chloride
- Pigmentation lightening test The back of an English brown guinea pig is shaved and irradiated with ultraviolet light (UVB intensity: 1 J / cm 2 ) twice a week for two consecutive weeks. After leaving it for one week, stable pigmented sites are removed. Obtained. Next, for each of the pigmented sites, the samples obtained in Examples or Comparative Examples were subjected to cumulative application once a day for four consecutive weeks. At the beginning of each week, the degree of pigmentation was visually determined according to the criteria shown below, and the pigmentation lightening effect was evaluated. In some experiments, the lightness (L) of the pigmented site was measured using a colorimeter.
- UVB intensity 1 J / cm 2
- Example 4 and Comparative Examples 4 and 11 skin permeability of linoleic acid was evaluated.
- the back skin of the hairless mouse was excised and stuck to a diffusion cell using physiological saline as a reservoir solution.
- the skin penetration rate of linoleic acid at each time point was calculated assuming that linoleic acid contained in the applied sample was 100.
- the pigmentation lightening effect is not observed unless the concentration of the unsaturated fatty acid or its derivative exceeds 1% by weight.
- cosmetics lacking any one of the essential components of the present invention have a weak pigmentation and lightening effect.
- Hydrolyzed elastin solution and sodium hyaluronate were dissolved in purified water. Separately mix arlinolenic acid, soy lecithin and vitamin E and add to the above aqueous solution. Glycerin, cunic acid, sodium citrate, ethanol, methyl paraoxybenzoate, and fragrance were added thereto, and the mixture was stirred well to obtain a lotion.
- the mixed phase A was mixed with the mixed and dissolved phase B.
- C phase and D phase respectively After heating and dissolving, phase C was mixed with phase D and emulsified with an emulsifier. Then, the mixed phase A was mixed, stirred and cooled to obtain a cream (PH 7.0).
- Linoleic acid 0, 1 0
- the mixed A phase and the uniformly mixed and dissolved B phase were mixed with a high-pressure homogenizer to prepare a liposome complex, and further mixed and stirred with the C phase to obtain a serum.
- the mixed phase A was uniformly heated and mixed.
- a pack was obtained by mixing and stirring the B phase mixed into the A phase in the course of cooling.
- phase A was mixed with the phase B, and the mixture was uniformly stirred and mixed.
- the mixed phase C was mixed with phase D, and this was mixed and stirred in the process of cooling phase B to obtain a cream mask.
- Methyl paraoxybenzoate 0.30 Decaglyceryl stearate 2.00 Carboxyvinyl polymer 0.10
- phase A was added to phase B and mixed and stirred.
- the C phase formed ribosomes using a French press, the particle size was adjusted using a filter, and then added to the D phase to prepare a ribosome complex.
- this ribosome complex was added to make an emulsion (pH 6.9).
- Polyethylene glycol 6 0 0 0 1 0 .0 0
- phase B was mixed with the phase C.
- phase C was mixed and stirred, and this was used as a face wash.
- Methyl paraoxybenzoate 0.20 Glycerin 8.00 Purified water Balance Trietanolamine Suitable amount (pH adjustment) POE (20) Sorbitan fatty acid ester 2.00
- the A phase and the B phase were uniformly heated and dissolved.
- the phase A was mixed with the phase B and mixed uniformly with stirring.
- yolk lecithin, linoleic acid monoglyceride, and vitamin E are mixed homogeneously, they are hydrated with an aqueous solution (pH 6) containing sodium hydroxide and 1,3-butylene glycol to form ribosomes (phase C).
- This C phase was mixed with the D phase, and this was mixed and stirred in the course of cooling the B phase to obtain a cream mask (pH 6.8).
- phase A The above components yolk lecithin, docosahexaenoic acid, and vitamin C were mixed in water, and ribosomes were formed using ultrasonic waves (phase A).
- the serum was obtained by mixing and stirring the phase A into the phase B, which was uniformly mixed and dissolved (pH 6.6).
- the whitening cosmetic composition of the present invention has a low content of unsaturated fatty acids at a low concentration, is less irritating at the time of use, is excellent in safety, and is remarkably excellent in pigmentation lightening effect.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019997011602A KR100554860B1 (ko) | 1997-06-10 | 1998-06-09 | 미백 화장품 재료 |
US09/445,562 US6669932B2 (en) | 1997-06-10 | 1998-06-09 | Skin-whitening cosmetic |
DE69812948T DE69812948T2 (de) | 1997-06-10 | 1998-06-09 | Hautaufhellendes kosmetisches mittel |
EP98923189A EP0992236B1 (en) | 1997-06-10 | 1998-06-09 | Skin-lightening cosmetic |
HK00105843A HK1026376A1 (en) | 1997-06-10 | 2000-09-15 | Skin-lightening cosmetic |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/169590 | 1997-06-10 | ||
JP16959097A JP3687277B2 (ja) | 1997-06-10 | 1997-06-10 | 美白化粧料 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998056338A1 true WO1998056338A1 (fr) | 1998-12-17 |
Family
ID=15889316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/002548 WO1998056338A1 (fr) | 1997-06-10 | 1998-06-09 | Produit cosmetique eclaircissant la peau |
Country Status (9)
Country | Link |
---|---|
US (1) | US6669932B2 (ja) |
EP (1) | EP0992236B1 (ja) |
JP (1) | JP3687277B2 (ja) |
KR (1) | KR100554860B1 (ja) |
CN (1) | CN1125634C (ja) |
DE (1) | DE69812948T2 (ja) |
HK (1) | HK1026376A1 (ja) |
TW (1) | TW381028B (ja) |
WO (1) | WO1998056338A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076464A2 (en) * | 1999-06-11 | 2000-12-21 | International Flora Technologies, Ltd. | Oxidatively stable, long-chain ethyl ester emollients |
WO2003066015A1 (en) * | 2002-02-02 | 2003-08-14 | Doosan Corporation | Composition for skin whitening containing lysophosphatidylethanolamine as an active ingredient |
EP1475080A2 (de) * | 2000-02-25 | 2004-11-10 | Kuhs GmbH & Co. KG | Kosmetische Zusammensetzung insbesondere zur Anwendung bei alternder und/oder gestresster Haut |
WO2006028199A1 (ja) * | 2004-09-10 | 2006-03-16 | Kose Corporation | 美白用皮膚外用剤及び美白方法 |
US20080260878A1 (en) * | 2004-09-22 | 2008-10-23 | Otsuka Pharmaceutical Co., Ltd. | Composition for Prevention or Alleviation of Pigmentation |
WO2012102364A1 (ja) * | 2011-01-27 | 2012-08-02 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JP6169240B1 (ja) * | 2016-10-28 | 2017-07-26 | サンスター株式会社 | リノール酸含有組成物 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894532A (en) * | 1988-03-28 | 1990-01-16 | Westinghouse Electric Corp. | Optical fiber sensor with light absorbing moisture-sensitive coating |
US6881427B2 (en) | 2002-01-31 | 2005-04-19 | Alticor Inc. | Topical anti-inflammatory composition containing linseed and licorice extracts |
JP3802011B2 (ja) * | 2003-06-16 | 2006-07-26 | 有限会社 シーバイオン | 美白剤 |
JP4653513B2 (ja) * | 2004-02-25 | 2011-03-16 | 株式会社コーセー | 皮膚外用剤 |
FR2870741B1 (fr) * | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
WO2006085687A1 (ja) | 2005-02-14 | 2006-08-17 | Suntory Limited | ジホモ−γ−リノレン酸(DGLA)を有効成分として含んで成る組成物 |
FI20050453A0 (fi) | 2005-04-29 | 2005-04-29 | Aromtech Ltd | Ihonhoitokoostumus |
CN1742623A (zh) * | 2005-07-13 | 2006-03-08 | 凌沛学 | 透明质酸磷脂复合物及其制备方法 |
WO2007041627A1 (en) * | 2005-10-03 | 2007-04-12 | Pinsky Mark A | Compositions and methods for improved skin care |
JP2007126444A (ja) * | 2005-10-03 | 2007-05-24 | Kose Corp | 皮膚外用剤 |
US8518445B2 (en) * | 2006-01-20 | 2013-08-27 | Research Foundation Of The City University Of New York | Changing skin-color perception using quantum and optical principles in cosmetic preparations |
JP2007314427A (ja) * | 2006-05-23 | 2007-12-06 | Nippon Fine Chem Co Ltd | リポ酸含有複合体 |
JP2008094809A (ja) * | 2006-10-16 | 2008-04-24 | Kose Corp | リポソーム組成物およびそれを配合する化粧料、並びに皮膚外用剤 |
WO2008051557A2 (en) | 2006-10-24 | 2008-05-02 | Jormay, Inc. | Methods and compositions for treatment of skin conditions |
KR100824212B1 (ko) * | 2006-11-03 | 2008-04-24 | 김윤범 | 태반을 함유하는 피부보호용 조성물 및 그의 제조방법 |
FR2909554B1 (fr) * | 2006-12-08 | 2013-11-01 | Biorecept Lab | Composition cosmetique anti-rides comprenant de l'acide hyaluronique |
KR100753437B1 (ko) | 2007-01-17 | 2007-09-14 | (주)미시앙 | 홍삼 조사포닌과 감초,비오틴(Biotin),쿠퍼 펩타이드(Copper peptide), 사이토카인(Cytokines)을 함유한 나노 리포좀 입자 및 이를 함유한 헤어 케어용 화장료 |
US9657257B2 (en) * | 2007-05-10 | 2017-05-23 | Kimberly-Clark Worldwide, Inc. | Colorant neutralizer |
US20080276379A1 (en) * | 2007-05-10 | 2008-11-13 | Macdonald John Gavin | Methods for discharging colorants |
US20090062764A1 (en) * | 2007-08-30 | 2009-03-05 | Kimberly-Clark Worldwide, Inc. | Zoned application of decolorizing composition for use in absorbent articles |
KR100924643B1 (ko) * | 2007-10-12 | 2009-11-02 | 세원셀론텍(주) | 아텔로콜라겐을 포집한 리포좀의 제조방법 |
US20090169615A1 (en) * | 2007-12-26 | 2009-07-02 | Pinsky Mark A | Collagen Formulations for Improved Skin Care |
IL191123A0 (en) * | 2008-04-28 | 2009-02-11 | Meir Shinitzky | Composition comprising phospholipids in combination with ascorbic acid and cosmetic products comprising it |
DE102008032327A1 (de) * | 2008-07-09 | 2010-01-14 | Rovi Cosmetics International Gmbh | Kosmetisches oder pharmazeutisches Präparat zur topischen Applikation von mehrfach ungesättigten Fettsäuren |
KR101607166B1 (ko) * | 2008-10-01 | 2016-03-29 | (주)아모레퍼시픽 | 포스파티딜에탄올아민과 포스파티딜콜린을 포함한 리포좀을함유하는 피부 미백용 화장료 조성물 |
JP2010120860A (ja) * | 2008-11-17 | 2010-06-03 | Nippon Menaade Keshohin Kk | 美白剤 |
SI2679278T1 (en) * | 2008-11-20 | 2018-02-28 | Laboratori Derivati Organici S.P.A. | Dermatological compositions comprising heparan sulphate |
WO2010077165A1 (en) * | 2008-12-31 | 2010-07-08 | Obschestvo S Ogranichennoi Otvetstvennostju Scientific Company Flamena | Phospholipid emulsion containing dihydroquercetin, and method of producing thereof |
JP5951173B2 (ja) * | 2009-01-09 | 2016-07-13 | ロート製薬株式会社 | ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制方法 |
DE102009029194A1 (de) | 2009-09-04 | 2011-04-07 | Kimberly-Clark Worldwide, Inc., Neenah | Abtrennung gefärbter Stoffe aus wasserhaltigen Flüssigkeiten |
JP5695308B2 (ja) * | 2009-10-02 | 2015-04-01 | 株式会社フェース | コラーゲン修飾リポソームからなる化粧料基剤およびそれを含有する皮膚化粧料 |
JP5756602B2 (ja) * | 2010-04-16 | 2015-07-29 | 株式会社フェース | ゼラチンおよび/またはエラスチン構成ポリペプチドで修飾されたリポソームからなる化粧料基剤およびそれを含有する皮膚化粧料 |
FR2962044B1 (fr) * | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
KR101796694B1 (ko) * | 2010-11-30 | 2017-11-13 | (주)아모레퍼시픽 | 피부 미백 및 탄력 제고 화장료 조성물 |
WO2012094638A1 (en) * | 2011-01-07 | 2012-07-12 | Skinmedica, Inc. | Melanin modification compositions and methods of use |
CN103327965B (zh) * | 2011-01-25 | 2017-07-18 | 宝洁公司 | 脂质体和包含脂质体的个人护理组合物 |
TW201334803A (zh) * | 2012-02-20 | 2013-09-01 | Taiwan Sugar Corp | 肝素用於皮膚保濕與美白及防止皮膚老化之新穎用途 |
US9283127B2 (en) | 2012-03-30 | 2016-03-15 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with decolorizing structures |
JP2015523333A (ja) * | 2012-05-16 | 2015-08-13 | コシードバイオファーム カンパニー リミテッド | 魚類眼球の破砕物又は抽出物を含有する化粧料、薬学及び食品組成物 |
US9441051B2 (en) * | 2012-11-26 | 2016-09-13 | Albert Ludwigs Universitäfreiburg | Matrices comprising modified polysaccharides and modified polysaccharides |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
US9237975B2 (en) | 2013-09-27 | 2016-01-19 | Kimberly-Clark Worldwide, Inc. | Absorbent article with side barriers and decolorizing agents |
CN104042547B (zh) * | 2014-06-16 | 2015-09-16 | 诺斯贝尔(中山)无纺日化有限公司 | 一种含卵磷脂的美白保湿天丝面膜液 |
SG11201707136PA (en) * | 2015-03-02 | 2017-10-30 | Amorepacific Corp | Multilamella nanoliposome which contains skin lipid components, and preparation method therefor |
CN105726348B (zh) * | 2016-02-23 | 2018-10-02 | 付涛 | 化妆品用组合物 |
US10253090B2 (en) | 2016-03-22 | 2019-04-09 | Avicenna Nutraceutical, Llc | Hydrolyzed collagen compositions and methods of making thereof |
CN107551390A (zh) * | 2017-08-21 | 2018-01-09 | 常熟佳禾生物科技有限公司 | 一种用于治疗乳腺小叶增生的中药文胸贴片及其制备方法 |
CN107569436B (zh) * | 2017-09-26 | 2020-12-15 | 北京斯利安药业有限公司 | 一种护肤组合物、柔肤水及其制备方法 |
DE102018201598A1 (de) * | 2018-02-02 | 2019-08-08 | Beiersdorf Ag | Stabile Wundheilsalbe |
JP7158922B2 (ja) * | 2018-06-29 | 2022-10-24 | サンスター株式会社 | リノール酸を含有する組成物 |
KR20210107772A (ko) * | 2018-12-26 | 2021-09-01 | 니폰 세이카 가부시키가이샤 | 미백제, 히알루론산 생성 촉진제, 콜라겐 생성 촉진제, 세포내 활성 산소 소거제, 자극 완화제, 주름 개선제, 복합체, 화장료 및 피부 외용제 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63239208A (ja) * | 1987-01-19 | 1988-10-05 | パルファン ロシャス | シリマリンが豊富に含まれるオオアザミの果実の抽出物と不可欠脂肪酸を含む美容用または皮膚用組成物 |
JPH02207013A (ja) * | 1989-02-07 | 1990-08-16 | Sunstar Inc | 美白化粧料 |
JPH0539485A (ja) * | 1991-08-02 | 1993-02-19 | Kose Corp | 液晶組成物及びこれを含有する化粧料 |
JPH07509001A (ja) * | 1992-08-04 | 1995-10-05 | ローネ−パウレンク ロレル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物及び/又は化粧品組成物、及びそれらの使用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327330D0 (en) * | 1983-10-12 | 1983-11-16 | Parsons W J | Membrane analogue emulsions |
ATE82684T1 (de) * | 1984-03-07 | 1992-12-15 | Roshdy Ismail | Mittel zur behandlung und zum schutz der haut. |
US5279834A (en) * | 1987-06-12 | 1994-01-18 | Lvmh Recherche | Pharmaceutical or cosmetic composition containing hydroquinone and kojic acid |
JP2614474B2 (ja) * | 1988-01-20 | 1997-05-28 | サンスター株式会社 | 美白化粧料 |
JP2553474B2 (ja) * | 1988-09-29 | 1996-11-13 | 鐘紡株式会社 | 皮膚化粧料 |
EP0561305B1 (en) * | 1992-03-17 | 1999-08-11 | Eisai Co., Ltd. | Skin whitening composition containing teprenone |
JP2722309B2 (ja) * | 1992-05-15 | 1998-03-04 | 株式会社資生堂 | 皮膚外用剤 |
GB2283173A (en) | 1993-10-28 | 1995-05-03 | Sansho Seiyaku Kk | Epidermal composition comprising kojic acid and an ultra-violet light absorbent |
FR2751535B1 (fr) * | 1996-07-25 | 1998-11-27 | Oreal | Utilisation de derives de la melatonine pour la la depigmentation de la peau et compositions les comprenant |
JPH10186811A (ja) | 1996-12-27 | 1998-07-14 | Konica Corp | 放電ワイヤの清掃装置 |
US6174533B1 (en) * | 1997-05-23 | 2001-01-16 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US5980904A (en) * | 1998-11-18 | 1999-11-09 | Amway Corporation | Skin whitening composition containing bearberry extract and a reducing agent |
-
1997
- 1997-06-10 JP JP16959097A patent/JP3687277B2/ja not_active Expired - Lifetime
-
1998
- 1998-06-09 US US09/445,562 patent/US6669932B2/en not_active Expired - Lifetime
- 1998-06-09 EP EP98923189A patent/EP0992236B1/en not_active Expired - Lifetime
- 1998-06-09 DE DE69812948T patent/DE69812948T2/de not_active Expired - Lifetime
- 1998-06-09 KR KR1019997011602A patent/KR100554860B1/ko not_active IP Right Cessation
- 1998-06-09 TW TW087109143A patent/TW381028B/zh not_active IP Right Cessation
- 1998-06-09 WO PCT/JP1998/002548 patent/WO1998056338A1/ja active IP Right Grant
- 1998-06-09 CN CN98808102A patent/CN1125634C/zh not_active Expired - Lifetime
-
2000
- 2000-09-15 HK HK00105843A patent/HK1026376A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63239208A (ja) * | 1987-01-19 | 1988-10-05 | パルファン ロシャス | シリマリンが豊富に含まれるオオアザミの果実の抽出物と不可欠脂肪酸を含む美容用または皮膚用組成物 |
JPH02207013A (ja) * | 1989-02-07 | 1990-08-16 | Sunstar Inc | 美白化粧料 |
JPH0539485A (ja) * | 1991-08-02 | 1993-02-19 | Kose Corp | 液晶組成物及びこれを含有する化粧料 |
JPH07509001A (ja) * | 1992-08-04 | 1995-10-05 | ローネ−パウレンク ロレル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤組成物及び/又は化粧品組成物、及びそれらの使用 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0992236A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076464A2 (en) * | 1999-06-11 | 2000-12-21 | International Flora Technologies, Ltd. | Oxidatively stable, long-chain ethyl ester emollients |
WO2000076464A3 (en) * | 1999-06-11 | 2001-07-05 | Int Flora Technologies Ltd | Oxidatively stable, long-chain ethyl ester emollients |
EP1475080A2 (de) * | 2000-02-25 | 2004-11-10 | Kuhs GmbH & Co. KG | Kosmetische Zusammensetzung insbesondere zur Anwendung bei alternder und/oder gestresster Haut |
EP1475080A3 (de) * | 2000-02-25 | 2007-01-31 | Kuhs GmbH & Co. KG | Kosmetische Zusammensetzung insbesondere zur Anwendung bei alternder und/oder gestresster Haut |
WO2003066015A1 (en) * | 2002-02-02 | 2003-08-14 | Doosan Corporation | Composition for skin whitening containing lysophosphatidylethanolamine as an active ingredient |
WO2006028199A1 (ja) * | 2004-09-10 | 2006-03-16 | Kose Corporation | 美白用皮膚外用剤及び美白方法 |
US20080260878A1 (en) * | 2004-09-22 | 2008-10-23 | Otsuka Pharmaceutical Co., Ltd. | Composition for Prevention or Alleviation of Pigmentation |
WO2012102364A1 (ja) * | 2011-01-27 | 2012-08-02 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JPWO2012102364A1 (ja) * | 2011-01-27 | 2014-06-30 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
US8940312B2 (en) | 2011-01-27 | 2015-01-27 | Sunstar Inc. | Composition containing polyunsaturated fatty acid |
JP6137836B2 (ja) * | 2011-01-27 | 2017-05-31 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JP2017114895A (ja) * | 2011-01-27 | 2017-06-29 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JP6169240B1 (ja) * | 2016-10-28 | 2017-07-26 | サンスター株式会社 | リノール酸含有組成物 |
WO2018079688A1 (ja) * | 2016-10-28 | 2018-05-03 | サンスター株式会社 | リノール酸含有組成物 |
JP2018070501A (ja) * | 2016-10-28 | 2018-05-10 | サンスター株式会社 | リノール酸含有組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1125634C (zh) | 2003-10-29 |
US6669932B2 (en) | 2003-12-30 |
JP3687277B2 (ja) | 2005-08-24 |
HK1026376A1 (en) | 2000-12-15 |
US20030103916A1 (en) | 2003-06-05 |
DE69812948D1 (de) | 2003-05-08 |
TW381028B (en) | 2000-02-01 |
EP0992236B1 (en) | 2003-04-02 |
KR100554860B1 (ko) | 2006-02-24 |
DE69812948T2 (de) | 2003-11-13 |
EP0992236A4 (en) | 2002-01-09 |
JPH111423A (ja) | 1999-01-06 |
EP0992236A1 (en) | 2000-04-12 |
KR20010013593A (ko) | 2001-02-26 |
CN1266367A (zh) | 2000-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998056338A1 (fr) | Produit cosmetique eclaircissant la peau | |
WO2004071472A1 (ja) | α,α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 | |
WO2007013662A1 (ja) | しわ防止・改善剤 | |
HUT71728A (en) | Slimming composition for topical treatment, containing two types of liposomes, and use thereof | |
WO2006033343A1 (ja) | 色素沈着予防又は改善用組成物 | |
JP2000212082A (ja) | 皮膚用剤 | |
JP2005179313A (ja) | 皮膚化粧料用基剤の製造方法および皮膚化粧料 | |
JP4080946B2 (ja) | 皮膚外用剤 | |
JP2004115381A (ja) | 皮膚外用剤 | |
JP2002145751A (ja) | アスコルビン酸類を含む皮膚外用剤 | |
JPH05201847A (ja) | 美白化粧料 | |
JP3170024B2 (ja) | 美白化粧料 | |
JPH0193520A (ja) | 美白化粧料 | |
JP4592347B2 (ja) | 外用剤組成物 | |
WO2005032504A1 (en) | Cosmetic preparation containing high molecular antioxidant component | |
JP2005179238A (ja) | 皮膚外用剤 | |
JP2860902B2 (ja) | 皮膚外用剤 | |
JPH05194176A (ja) | 美白化粧料 | |
JP2000053529A (ja) | 皮膚外用剤 | |
JPH11130615A (ja) | リポソーム分散液の製造方法及びそれを用いた化粧料 | |
JPH0873311A (ja) | 皮膚外用剤 | |
JP5329489B2 (ja) | 外用剤組成物 | |
KR101906559B1 (ko) | 해초 다당류 발효액을 함유한 화장료 조성물 | |
JPH07309738A (ja) | 美白化粧料 | |
JPH09202711A (ja) | 美白剤及び外用剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808102.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): DE FR GB |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998923189 Country of ref document: EP Ref document number: 1019997011602 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09445562 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998923189 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997011602 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998923189 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997011602 Country of ref document: KR |